Single center, double-blind, randomized, placebo-controlled, two-period/two-treatment crossover, proof-of-mechanism study investigating the effect of miglustat on the nasal potential difference in adult patients with cystic fibrosis homozygous for the F508del mutation
Phase of Trial: Phase II/III
Latest Information Update: 04 Aug 2016
At a glance
- Drugs Miglustat (Primary)
- Indications Cystic fibrosis
- Focus Pharmacodynamics; Proof of concept
- Acronyms MIGLUSTAT-CF
- 31 Jul 2016 Planned End Date changed from 1 Aug 2017 to 1 Jan 2018.
- 31 Jul 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Sep 2017.
- 20 Apr 2015 Planned End Date changed from 1 Jun 2017 to 1 Aug 2017 as per ClinicalTrials.gov record.